{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:37:08Z","timestamp":1793831828398,"version":"4.6.1"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejmech.2022.114442","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T15:23:06Z","timestamp":1651850586000},"page":"114442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["The progress of small-molecules and degraders against BCR-ABL for the treatment of CML"],"prefix":"10.1016","volume":"238","author":[{"given":"You-lu","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-xin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-rong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-rong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-hai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114442_bib1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.286.8.895","article-title":"Chronic myelogenous leukemia","volume":"286","author":"Kalidas","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114442_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114442_bib3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114442_bib4","first-page":"55","article-title":"Chronic myeloid leukemia: attributes of break point cluster region-abelson (BCR-ABL)","volume":"3","author":"Rana","year":"2011","journal-title":"J. Cancer Res. Exp. Oncol."},{"key":"10.1016\/j.ejmech.2022.114442_bib5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114442_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","article-title":"The BCR-ABL story: bench to bedside and back","volume":"22","author":"Wong","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2022.114442_bib7","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib8","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1021\/acs.jmedchem.5b01125","article-title":"Development of alkyne-containing pyrazolopyrimidines to overcome drug resistance of bcr-abl kinase","volume":"58","author":"Liu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib9","doi-asserted-by":"crossref","first-page":"113867","DOI":"10.1016\/j.ejmech.2021.113867","article-title":"Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: an extensive review","volume":"226","author":"Garrido","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995\u20132021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib11","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41467-017-02313-6","article-title":"Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase","volume":"8","author":"Reckel","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114442_bib12","first-page":"117","article-title":"Structure of the Bcr-Abl oncoprotein oligomerization domain","volume":"9","author":"Zhao","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejmech.2022.114442_bib13","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.V95.6.2118","article-title":"STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells","volume":"95","author":"Sillaber","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib14","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114442_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molcel.2005.06.030","article-title":"Structural basis for the cytoskeletal association of bcr-abl\/c-abl","volume":"19","author":"Hantschel","year":"2005","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114442_bib16","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66 11","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/aps.2009.19","article-title":"Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo","volume":"30","author":"Wei","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114442_bib18","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ar.20924","article-title":"The antiproliferation effect of berbamine on K562 resistant cells by inhibiting NF-\u03baB pathway","volume":"292","author":"Wei","year":"2009","journal-title":"Anat. Rec."},{"key":"10.1016\/j.ejmech.2022.114442_bib19","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/aps.2009.167","article-title":"Berbamine, a novel nuclear factor \u03baB inhibitor, inhibits growth and induces apoptosis in human myeloma cells","volume":"30","author":"Liang","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114442_bib20","first-page":"1997","article-title":"Inhibitory effect of 4-chlorobenzoyl berbamine on imatinib-resistant K562 cells in vitro and in vivo","volume":"31","author":"Zhang","year":"2011","journal-title":"J. South. Med. Univ."},{"key":"10.1016\/j.ejmech.2022.114442_bib21","first-page":"78","article-title":"Effect of homoharringtonine on expression of NF-\u03baB and BCL-2 proteins in K562 cells","volume":"21","author":"Ye","year":"2013","journal-title":"J. Exp. Hematol."},{"key":"10.1016\/j.ejmech.2022.114442_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1600-0609.2008.01116.x","article-title":"Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells","volume":"81","author":"Tong","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmech.2022.114442_bib23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1631\/jzus.B1200021","article-title":"Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl\/\u03b2-catenin axis","volume":"13","author":"Xu","year":"2012","journal-title":"J. Zhejiang Univ. - Sci. B"},{"key":"10.1016\/j.ejmech.2022.114442_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1078-0432.CCR-13-1063","article-title":"Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent bcr-abl downregulation","volume":"20","author":"Shi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canlet.2009.09.006","article-title":"Celastrol, a novel HSP90 inhibitor, depletes Bcr\u2013Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"290","author":"Lu","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2022.114442_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1745-7254.2006.00291.x","article-title":"Curcumin inhibits WT1 gene expression in human leukemic K562 cells","volume":"27","author":"Anuchapreeda","year":"2006","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.114442_bib27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00018-009-0233-x","article-title":"The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition","volume":"67","author":"Giommarelli","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2022.114442_bib28","doi-asserted-by":"crossref","first-page":"109091","DOI":"10.1016\/j.biopha.2019.109091","article-title":"Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer","volume":"117","author":"Choi","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114442_bib29","doi-asserted-by":"crossref","first-page":"173366","DOI":"10.1016\/j.ejphar.2020.173366","article-title":"Targeting SKP2\/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation","volume":"883","author":"Liu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114442_bib30","first-page":"1799","article-title":"Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts","volume":"61","author":"Nimmanapalli","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/biof.5520340407","article-title":"Radicicol-mediated inhibition of Bcr-Ab1 in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation","volume":"34","author":"Morceau","year":"2008","journal-title":"Biofactors"},{"key":"10.1016\/j.ejmech.2022.114442_bib32","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114442_bib33","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","article-title":"ARG tyrosine kinase activity is inhibited by STI571","volume":"97","author":"Okuda","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib34","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib35","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","article-title":"Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis","volume":"23","author":"Gambacorti-Passerini","year":"1997","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejmech.2022.114442_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL","volume":"11","author":"Nardi","year":"2004","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.ejmech.2022.114442_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"Cowan-Jacob","year":"2007","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.ejmech.2022.114442_bib39","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-m ethylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib40","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah Neil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114442_bib42","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib43","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias","volume":"109","author":"Weisberg","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib44","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschembio.5b01018","article-title":"Conformation-selective analogues of dasatinib reveal insight into kinase inhibitor binding and selectivity","volume":"11","author":"Kwarcinski","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114442_bib45","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.ejca.2010.02.032","article-title":"Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia","volume":"46","author":"Boschelli","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2022.114442_bib46","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/leu.2015.42","article-title":"Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1","volume":"29","author":"Zabriskie","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114442_bib47","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of Radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.476.476","article-title":"Efficacy and safety of Radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia patients: 12 Months result of phase 3 clinical trial","volume":"126","author":"Kwak","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib49","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/leu.2010.169","article-title":"HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance","volume":"24","author":"Luo","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114442_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/cas.12320","article-title":"Flumatinib, a selective inhibitor of BCR-ABL\/PDGFR\/KIT, effectively overcomes drug resistance of certain KIT mutants","volume":"105","author":"Zhao","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114442_bib51","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1124\/dmd.110.032326","article-title":"Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients","volume":"38","author":"Gong","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2022.114442_bib52","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114442_bib53","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114442_bib54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114442_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","article-title":"Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance","volume":"77","author":"Zhou","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2022.114442_bib56","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib57","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114442_bib58","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/jch.13843","article-title":"Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib","volume":"22","author":"Amin","year":"2020","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ejmech.2022.114442_bib59","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","article-title":"INNO-406, a novel BCR-ABL\/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity","volume":"109","author":"Yokota","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib60","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.bmcl.2007.03.002","article-title":"Structural factors contributing to the Abl\/Lyn dual inhibitory activity of 3-substituted benzamide derivatives","volume":"17","author":"Horio","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114442_bib61","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.2174\/092986708786848578","article-title":"Targeted drugs in chronic myeloid leukemia","volume":"15","author":"Gora-Tybor","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib62","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/acs.jmedchem.5b01618","volume":"59","author":"Liang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib63","doi-asserted-by":"crossref","first-page":"45562","DOI":"10.18632\/oncotarget.10037","article-title":"Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114442_bib64","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.jmedchem.6b01290","article-title":"Discovery of 4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL\/KIT-155) as a novel highly potent type II ABL\/KIT dual kinase inhibitor with a distinct hinge binding","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib65","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2021.1990034","article-title":"Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"14","author":"Malik","year":"2021","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.ejmech.2022.114442_bib66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.exphem.2019.08.007","article-title":"BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia","volume":"77","author":"Antelope","year":"2019","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2022.114442_bib67","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1021\/jm201454n","volume":"55","author":"William","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib68","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/acs.jmedchem.0c01467","article-title":"Recent developments in the use of kinase inhibitors for management of viral infections","volume":"65","author":"Raghuvanshi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib69","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2022.114442_bib70","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11899-020-00596-z","article-title":"The next generation of JAK inhibitors: an update on fedratinib, momelotonib, and pacritinib","volume":"15","author":"Patel","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ejmech.2022.114442_bib71","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","article-title":"Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies","volume":"9","author":"Verstovsek","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114442_bib72","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Kimura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib73","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/15384047.2019.1579958","article-title":"Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)","volume":"20","author":"Wu","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2022.114442_bib74","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/acs.jmedchem.5b01618","volume":"59","author":"Liang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib75","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.jmedchem.6b01290","article-title":"Discovery of 4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-n icotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL\/KIT-155) as a novel highly potent type II ABL\/KIT dual kinase inhibitor with a distinct hinge binding","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib76","first-page":"289","article-title":"PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells","volume":"55","author":"Ivanova","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2022.114442_bib77","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib78","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114442_bib79","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2022.114442_bib80","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543784.2012.652303","article-title":"Danusertib, an aurora kinase inhibitor","volume":"21","author":"Meulenbeld","year":"2012","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114442_bib81","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1158\/0008-5472.CAN-07-1825","article-title":"Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358","volume":"67","author":"Modugno","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib82","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib83","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3324\/haematol.2014.115279","volume":"100","author":"Borthakur","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2022.114442_bib84","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.drudis.2013.06.001","article-title":"The background, discovery and clinical development of BCR-ABL inhibitors","volume":"18","author":"Lambert","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114442_bib85","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/0008-5472.CAN-05-2788","article-title":"Structure of the kinase domain of an imatinib-resistant abl mutant in complex with the aurora kinase inhibitor VX-680","volume":"66","author":"Young","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib86","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells","volume":"15","author":"Bu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2022.114442_bib87","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14756366.2016.1250757","article-title":"Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl(T315I) inhibitor overcoming acquired imatinib resistance","volume":"32","author":"Lu","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib88","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cmdc.201700829","article-title":"Alkynylnicotinamide-based compounds as ABL1 inhibitors with potent activities against drug-resistant CML harboring ABL1(t315I) mutant kinase","volume":"13","author":"Larocque","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114442_bib89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2017.06.001","article-title":"SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia","volume":"811","author":"Wang","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114442_bib90","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-1327","article-title":"Abstract 1327: UM-9107: a selective wild-type and T315I Bcr-Abl inhibitor with in vivo activity against chronic myelogenous leukemia","volume":"79","author":"Phadke","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib91","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2016.152710","article-title":"Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia","volume":"102","author":"Cortes","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2022.114442_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114442_bib93","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114442_bib94","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2009-03-211466","article-title":"Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL\u2013positive leukemic cells","volume":"116","author":"Tanaka","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib95","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/annonc\/mdr451","article-title":"A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies","volume":"23","author":"Arkenau","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2022.114442_bib96","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2009-01-199307","article-title":"KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR\/ABL translocation","volume":"114","author":"Shiotsu","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib97","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1021\/op400137m","article-title":"Process development and multikilogram syntheses of XL228 utilizing a regioselective isoxazole formation and a selective SNAr reaction to a pyrimidine core","volume":"17","author":"Guz","year":"2013","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2022.114442_bib98","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V112.11.3232.3232","article-title":"Preliminary clinical activity in a phase I trial of the BCR-ABL\/IGF-1R\/Aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T3151 mutation","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114442_bib99","doi-asserted-by":"crossref","first-page":"112981","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib100","doi-asserted-by":"crossref","first-page":"10927","DOI":"10.1021\/acs.jmedchem.9b00446","article-title":"Drug discovery targeting anaplastic lymphoma kinase (ALK)","volume":"62","author":"Kong","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib101","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2022.114442_bib102","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1021\/acs.jmedchem.9b02058","article-title":"Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib103","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114442_bib104","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/DDDT.S132092","article-title":"Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines","volume":"11","author":"Xin","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2022.114442_bib105","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1039\/D0CC02201B","article-title":"Scaffold hopping enables direct access to more potent PROTACs with in vivo activity","volume":"56","author":"Burslem","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2022.114442_bib106","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting Von hippel\u2013lindau (VHL) E3 ubiquitin ligase","volume":"62","author":"Zhao","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib107","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","article-title":"Global PROTAC toolbox for degrading BCR\u2013ABL overcomes drug-resistant mutants and adverse effects","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114442_bib108","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canlet.2019.11.040","article-title":"Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia","volume":"472","author":"Gupta","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2022.114442_bib109","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1016\/j.bmcl.2016.09.041","article-title":"Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand","volume":"26","author":"Demizu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114442_bib110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114442_bib111","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114442_bib112","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1021\/acsmedchemlett.7b00247","article-title":"Targeting the allosteric site of oncoprotein BCR-ABL as an alternative strategy for effective target protein degradation","volume":"8","author":"Shimokawa","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114442_bib113","doi-asserted-by":"crossref","first-page":"13549","DOI":"10.1038\/s41598-018-31913-5","article-title":"Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase","volume":"8","author":"Shibata","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114442_bib114","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","article-title":"Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate","volume":"14","author":"Brave","year":"2008","journal-title":"Clin. Cancer Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422003440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T14:10:26Z","timestamp":1728396626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422003440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":114,"alternative-id":["S0223523422003440"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114442","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The progress of small-molecules and degraders against BCR-ABL for the treatment of CML","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114442"}}